Skip to main content
Equibles
CRSP logo

CRSP · CRISPR Therapeutics AG · Metrics

Track CRSP — free

Use CRSP with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research CRSP.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$49.39 -0.60 (-1.20%) At close · Oct 23
Russell 2000 member Rebalance outlook locked
Market Cap
$4.78B
Shares
96.69M
Volume · Oct 23 2.12M Avg daily vol (3M) 1.56M

CRSP metrics

91 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$49.39
Market cap
$4.78B

Price action

20 metrics
Price change (1W)
+0.3%
Price change (30D)
-8.9%
Price change (3M)
+6.1%
Price change (6M)
+1.2%
Price change (YTD)
-5.8%
Price change (1Y)
-26.5%
Trailing year
Price change (5Y)
-48.3%
52-week high
$67.61
52-week low
$44.34
Change from 52-week high
-26.9%
Change from 52-week low
+11.4%
Annualized volatility
57.3%
Annualized volatility (3M)
52.5%
Beta
1.9
RSI (14D)
40.5
Price vs SMA 50
-9.5%
Price vs SMA 200
-6.8%
Avg volume (3M)
1.56M
Relative volume
1.4
Average dollar volume
$84.34M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
96.69M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
223.8×
reciprocal yield 0.4%
EV / EBITDA
—
EV / EBIT
—
P / sales
356.6×
reciprocal yield 0.3%
P / book
2.7
reciprocal yield 36.6%
FCF yield
-7.8%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-9.4%

Historical valuation

8 metrics
P / E historical average (3Y)
39.5×
reciprocal yield 2.5%
P / E historical average (5Y)
39.5×
reciprocal yield 2.5%
EV / revenue historical average (3Y)
163.7×
reciprocal yield 0.6%
EV / revenue historical average (5Y)
207.6×
reciprocal yield 0.5%
EV / EBIT historical average (3Y)
33.1×
reciprocal yield 3.0%
EV / EBIT historical average (5Y)
33.1×
reciprocal yield 3.0%
EV / EBITDA historical average (3Y)
407.4×
reciprocal yield 0.2%
EV / EBITDA historical average (5Y)
407.4×
reciprocal yield 0.2%

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
—
Operating margin
-3,990.0%
Trailing 12 months
Net margin
-3,368.7%
Gross profit (TTM)
—
Operating profit (TTM)
−$534.34M
Net income (TTM)
−$451.14M
Trailing 12 months
Diluted EPS (TTM)
$-4.71
FCF margin
-2,772.7%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$0.14
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-5.64
EBITDA per diluted share (TTM)
$-5.44
Net income per diluted share (TTM)
$-4.76
Operating cash flow per diluted share (TTM)
$-3.90
Free cash flow per diluted share (TTM)
$-3.92
Capital expenditures per diluted share (TTM)
$0.02
R&D per diluted share (TTM)
$2.93
Stock compensation per diluted share (TTM)
$0.72
Book value per share
$20.04

Growth

11 metrics
Revenue growth YoY
+1,041.4%
Year over year
Net income growth YoY
—
Revenue (TTM)
$13.39M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+10.8%
Year over year · more shares
Revenue CAGR (3Y)
+43.1%
Revenue CAGR (5Y)
+37.3%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-25.8%
Return on assets
-17.0%
Debt / equity
0.3
Current ratio
17.8
EBITDA (TTM)
−$515.65M
Free cash flow (TTM)
−$371.32M
Quick ratio
17.8
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$1.78B
Latest balance sheet
Cash & equivalents
$291.34M
Total assets
$2.65B
Total debt
$586.20M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$369.58M
Capital expenditures (TTM)
$1.74M
R&D (TTM)
$278.15M
SG&A (TTM)
—
Stock compensation (TTM)
$68.32M
R&D / revenue
2,077.0%
Stock compensation / revenue
510.2%

Ownership (13F)

9 metrics
13F filers
530
13F filer change QoQ
+30
Institutional ownership
81.5%
Conviction holders (share of 13F filers)
1.1%
Crowding (high-turnover and private-fund holders)
22.5%
Private-fund adviser ownership
20.8%
Active holders' share change QoQ
-4.2%
Holder tenure
15.8
Price vs estimated holder cost
-1.9%

Ownership (registered funds)

1 metrics
Index-fund ownership
2.5%

Short interest

3 metrics
Short interest
19.3%
Latest settlement · 9.6 days to cover
Days to cover
9.6d
Short-squeeze score
74 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$4.88M
Insider-sentiment score
17 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1674416 CUSIP H17182108 13F (30d) 89 filings 89 filers Visit website Investor relations